| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| Other Sizes |
| Targets |
The primary target of Mogroside VI B is the transcriptional coactivator PGC-1α (peroxisome proliferator-activated receptor gamma coactivator 1-alpha). Mogroside VI B shows an effect on activating PGC-1α transcription. By modulating PGC-1α activity, the compound may influence various metabolic processes, including mitochondrial biogenesis, glucose and lipid metabolism, and thermogenesis. This makes it a valuable tool for studying metabolic disorders such as obesity and diabetes.
|
|---|---|
| ln Vitro |
Mogroside VI B exhibits mild impacts on the activity of the PGC-1α promoter. Mogroside VI B has the ability to stimulate PGC-1α at a concentration of 20 μM[1].
In vitro, Mogroside VI B has been shown to activate PGC-1α transcription. This activity was identified in studies using reporter gene assays. The compound's ability to modulate PGC-1α expression makes it a useful tool for studying the regulation of energy metabolism at the molecular level. |
| ln Vivo |
In vivo, Mogroside VI B may have potential metabolic effects through its activation of PGC-1α transcription. By upregulating PGC-1α, the compound could enhance mitochondrial function and energy expenditure. However, detailed in vivo efficacy data are not extensively reported in the available literature.
|
| Enzyme Assay |
In vitro assays for Mogroside VI B typically involve cell-based reporter gene assays to measure PGC-1α promoter activity. Cells are transfected with a reporter construct containing the PGC-1α promoter and treated with the compound. The activation of the promoter is measured by quantifying the reporter signal.
|
| Cell Assay |
In vitro cellular assays for Mogroside VI B may involve the use of cell lines to study its effects on PGC-1α expression and downstream metabolic pathways. Cells are treated with the compound, and the expression of PGC-1α and its target genes is measured by qPCR or Western blotting.
|
| Animal Protocol |
In vivo animal studies for Mogroside VI B are not detailed in the available literature. As a research tool, it could be administered to rodent models of metabolic disease to assess its effects on energy metabolism, insulin sensitivity, and body weight.
|
| ADME/Pharmacokinetics |
Mogroside VI B has a molecular formula of C66H112O34 and a molecular weight of 1449.59. It is a solid with a density of 1.55±0.1 g/cm3 (predicted). It is typically stored under standard conditions. Detailed pharmacokinetic parameters are not available.
|
| Toxicity/Toxicokinetics |
There is no specific toxicity data reported for Mogroside VI B. As a research chemical, it should be handled with standard safety precautions.
|
| References | |
| Additional Infomation |
Mogroside VI B is a cucurbitane glucoside isolated from Siraitia grosvenorii (Luo Han Guo). It has a molecular formula of C66H112O34 and a molecular weight of 1449.59. It shows an effect on activating PGC-1α transcription.
|
| Molecular Formula |
C66H112O34
|
|---|---|
| Molecular Weight |
1449.57510566711
|
| Exact Mass |
1446.724
|
| CAS # |
2149606-17-5
|
| Appearance |
White to off-white solid powder
|
| Source |
Originated from plants: Cucurbitaceae Siraitia grosvenorii (Swingle) C. Jeffrey ex Lu et Z. Y. Zhang
|
| LogP |
-4.5
|
| SMILES |
C[C@]12C3CC[C@H](O[C@@H]4O[C@H](CO[C@@H]5O[C@H](CO)[C@@H](O)[C@H](O)[C@H]5O)[C@@H](O)[C@H](O)[C@H]4O)C(C3=CC[C@H]1[C@@]1(C)[C@@](C)([C@H](CC1)[C@@H](CC[C@@H](O[C@H]1[C@H](O[C@H]3[C@H](O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@@H](CO)O3)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)O1)C(C)(C)O)C)C[C@H]2O)(C)C
|
| InChi Key |
FRSXWRODNFMFEO-BSIITDIOSA-N
|
| InChi Code |
InChI=1S/C67H114O33/c1-25(27-15-16-65(6)37-13-11-28-29(67(37,8)38(72)18-66(27,65)7)12-14-39(63(28,2)3)98-60-54(87)49(82)44(77)36(97-60)24-91-59-53(86)47(80)41(74)32(20-69)94-59)9-10-26(64(4,5)89)17-30-56(50(83)45(78)35(92-30)23-90-58-52(85)46(79)40(73)31(19-68)93-58)99-62-57(51(84)43(76)34(22-71)96-62)100-61-55(88)48(81)42(75)33(21-70)95-61/h11,25-27,29-62,68-89H,9-10,12-24H2,1-8H3/t25-,26+,27?,29?,30+,31+,32-,33-,34+,35-,36-,37?,38-,39+,40+,41-,42-,43+,44-,45-,46-,47+,48+,49+,50+,51-,52+,53-,54-,55-,56+,57+,58+,59-,60+,61+,62-,65+,66-,67+/m0/s1
|
| Chemical Name |
(2R,3R,4S,5S,6R)-2-[[(2S,3R,4R,5S,6R)-5-[(2S,3R,4S,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2S,3S,4R,5R,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3,4-dihydroxy-6-[(2R,5S)-5-[(3R,9S,11S,13S,14R)-11-hydroxy-4,4,9,13,14-pentamethyl-3-[(2S,3S,4R,5R,6S)-3,4,5-trihydroxy-6-[[(2S,3S,4R,5R,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxy-2,3,7,8,10,11,12,15,16,17-decahydro-1H-cyclopenta[a]phenanthren-17-yl]-2-(2-hydroxypropan-2-yl)hexyl]oxan-2-yl]methoxy]-6-(hydroxymethyl)oxane-3,4,5-triol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: ~50 mg/mL (~34.5 mM; with ultrasonication)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 1.25 mg/mL (0.86 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween-80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), Clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (12.5 mg/mL) to 400 μL of PEG300 and mix well; then add 50 μL of Tween-80 and mix well; finally add 450 μL of physiological saline and adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 1.25 mg/mL (0.86 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), Clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (12.5 mg/mL) to 900 μL of 20% SBE-β-CD saline and mix well. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 3: ≥ 1.25 mg/mL (0.86 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), Clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (12.5 mg/mL) to 900 μL of corn oil and mix well. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.6899 mL | 3.4493 mL | 6.8985 mL | |
| 5 mM | 0.1380 mL | 0.6899 mL | 1.3797 mL | |
| 10 mM | 0.0690 mL | 0.3449 mL | 0.6899 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
